Observing the natural course of transthyretin amyloidosis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The MaesTTRo study is an international, longitudinal, non-interventional study that aims to enroll over 1,600 adult patients diagnosed with transthyretin (ATTR) amyloidosis. The study will collect primary data through patient-reported outcome questionnaires and secondary data from routine clinical practices to observe the disease's natural progression and treatment patterns. Patients will be followed for a minimum of 3 years, with data collected during routine visits, ensuring minimal disruption to their care. The study also aims to gather information on the effectiveness of treatments like eplontersen, a gene silencing therapy targeting TTR proteins.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patient willing and able to provide written informed consent to participate in the study
* Confirmed diagnosis of amyloid transthyretin (ATTR) amyloidosis
* Aged ≥18 years at the time of signing the informed consent
* Patient willing and able to participate in collection of electronic patient reported outcomes (PROs)

Exclusion Criteria:

* Concurrent participation in any interventional trial for ATTR amyloidosis
* Involvement in the planning and/or conduct of the current study
* Patients with evidence of primary or light chain amyloidosis (AL) or serum protein A amyloidosis (AA)
* Asymptomatic patients with ATTR amyloidosis and asymptomatic ATTR mutation carriers

Where it's running

• Research Site
  La Jolla, California, United States Recruiting
• Research Site
  Los Angeles, California, United States Recruiting
• Research Site
  San Francisco, California, United States Recruiting
• Research Site
  San Francisco, California, United States Recruiting
• Research Site
  New Haven, Connecticut, United States Recruiting
• Research Site
  Washington D.C., District of Columbia, United States Recruiting

+39 more sites. See ClinicalTrials.gov for the full list.

Study contacts

• Study coordinator: AstraZeneca Clinical Study Information Center
• Email: information.center@astrazeneca.com
• Phone: 1-877-240-9479

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Acoramidis for ATTR-CM: Cardiac Imaging Study

  This study tests whether acoramidis can improve heart structure and function in people with transthyretin amyloid cardiomyopathy.

  Recruiting Phase 4 Eidos Therapeutics, a BridgeBio company · St Louis, Missouri · NCT07695701

• Long-term safety of eplontersen in adults with transthyretin amyloidosis, including those with prior liver transplant or severe liver impairment

  This study will see if eplontersen remains safe over time for adults with transthyretin amyloidosis, including people who have had a liver transplant or have severe liver problems.

  Recruiting at 6 sites AstraZeneca · Los Angeles, California and 5 other locations · NCT07654855

• Annular ligament biopsy during endoscopic carpal tunnel surgery to screen for transthyretin amyloidosis

  This study tests whether a biopsy of the annular ligament during carpal tunnel surgery can reliably indicate transthyretin amyloidosis and match the results of the standard synovial biopsy.

  Recruiting Clinique Saint Jean, France · Montpellier · NCT07644325

• Eplontersen exposure during pregnancy and breastfeeding: outcomes

  This project collects reports to see if exposure to eplontersen during pregnancy or breastfeeding affects mothers, fetuses, or infants with transthyretin amyloidosis.

  Recruiting AstraZeneca · Frankfurt · NCT07205666

• Understanding Atrioventricular Regurgitation in ATTR Amyloid Cardiomyopathy

  This study is trying to understand how common certain heart valve problems are in people with ATTR amyloid cardiomyopathy and create better ways to measure their severity.

  Recruiting at 8 sites Medical University of Vienna · Graz, Styria and 7 other locations · NCT06836011

• Preventing transthyretin amyloidosis in young carriers of a genetic variant

  This study is testing if a medication called acoramidis can help prevent transthyretin amyloidosis in young adults who carry a specific genetic variant that puts them at risk for the disease.

  Recruiting at 104 sites Phase 3 Eidos Therapeutics, a BridgeBio company · La Jolla, California and 103 other locations · NCT06563895

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.